For the quarter ending 2025-09-30, ATOS made $9,821K in revenue. -$8,692K in net income. Net profit margin of -88.50%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 5,370 | 5,502 | ||
| General and administrative | 3,881 | 3,538 | ||
| Total operating expenses | 9,251 | 9,040 | ||
| Operating loss | -9,251 | -9,040 | ||
| Impairment charge on investment in equity securities | 0 | - | ||
| Interest income | 570 | 645 | ||
| Other expense, net | -11 | -28 | ||
| Loss before income taxes | -8,692 | -8,423 | ||
| Income taxes benefit | 0 | 0 | ||
| Net loss | -8,692 | -8,423 | ||
| Net loss per share of common stock - basic (in dollars per share) | -0.07 | -0.07 | ||
| Net loss per share of common stock - diluted (in dollars per share) | -0.07 | -0.07 | ||
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 129,171,424 | 129,170,425 | ||
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 129,171,424 | 129,170,425 | ||
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)